Crossmark

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Crossref DOI link: https://doi.org/10.1186/s40880-019-0405-5

Published Online: 2019-10-11

Published Print: 2019-12

Update policy: https://doi.org/10.1002/crossmark_policy

Authors

Cai, Wen

Cai, Biao

Zhou, Juan

Chen, Yonghui

Zhang, Jin

Huang, Yiran

Xue, Wei

Huang, Jiwei
Funding

Funding for this research was provided by:

Shanghai Science and Technology Commission (18ZR1423200)

Clinical Research and Innovation of Renji Hospital (PYXJS16-008)

Shen Kang 3-year action plan program (16CR3062B)
License Information

Version of Record valid from 2019-10-11
More Information

Publication History

Received: 2019-05-31

Accepted: 2019-09-27

Published: 2019-10-11